February 12, 2014 (Shareholders Foundation) - An investigation on behalf of investors of The Medicines Company (NASDAQ:MDCO) shares over potential securities laws violations by The Medicines Company and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of The Medicines Company (NASDAQ:MDCO) concerning whether a series of statements The Medicines Company regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

The Medicines Company reported that its annual Total Revnue rose from $404.24 million in 2009 to $558.59 million in 2012 and that its Net Loss of $76.23 million in 2009 into a Net Income of$127.88 million in 2011, respectively $51.25 million in 2012.

Shares of The Medicines Company (NASDAQ:MDCO) grew from $6.47 per share in May 2009 to as high as $40.39 per share on January 10, 2014.

Then on February 10, 2014, a report was published by the Food and Drug Administration ('FDA') regarding The Medicines Companys drug candidate Cangrelor, designed to prevent blood clots during heart artery-clearing angioplasty and stenting procedures. Then on February 12, 2014, The FDAs Cardiovascular and Renal Drugs Advisory Committee in 7-2 vote recommended against the approval of cangrelor.

Shares of The Medicines Company (NASDAQ:MDCO) declined from over $40 in early January 2014 to as low as $31.82 per share on February 11, 2014.